Meeting
2023 ASCO Annual Meeting
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
Presenter
Macarena Ines De La Fuente, MD
Sylvester Comprehensive Cancer Center, University of Miami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02428712
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3006)
DOI
10.1200/JCO.2023.41.16_suppl.3006
Abstract #
3006
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
Speaker: Jacob Stephen Thomas, MD
Speaker: Panel Discussion
Videos & Slides
2012 ASCO Annual Meeting
Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.
Speaker: Jeffrey S. Weber, MD, PhD
Videos & Slides
2011 ASCO Annual Meeting
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
Speaker: Jeffrey R. Infante, MD